• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Identification of a conformationally distinct form of plasminogen activator inhibitor-1, acting as a noninhibitory substrate for tissue-type plasminogen activator.

作者信息

Declerck P J, De Mol M, Vaughan D E, Collen D

机构信息

Center for Thrombosis and Vascular Research, University of Leuven, Belgium.

出版信息

J Biol Chem. 1992 Jun 15;267(17):11693-6.

PMID:1601844
Abstract

Plasminogen activator inhibitor-1 (PAI-1), the primary physiological inhibitor of tissue-type plasminogen activator (t-PA) in plasma, is a serine proteinase inhibitor (serpin) that forms a 1:1 stoichiometric complex with its target proteinase leading to the formation of a stable inactive complex. The active, inhibitory form of PAI-1 spontaneously converts to a latent form that can be reactivated by protein denaturants. In the present study we have isolated another molecular form of intact PAI-1 that, in contrast with active PAI-1, does not form stable complexes with t-PA but is cleaved at the P1-P1' bond (Arg346-Met347). Other serine proteinases, e.g. urokinase-type plasminogen activator and thrombin, also cleaved this "substrate" form of PAI-1. Fluorescence spectroscopy revealed conformational differences between the latent, active, and substrate forms of PAI-1. This observation confirms our hypothesis that the three functionally different forms of PAI-1 are the consequence of conformational transitions. Thus PAI-1 may occur in three interconvertible conformations: latent, inhibitor, and substrate PAI-1. The identification of two distinct conformations of PAI-1 which interact with their target protease either as an inhibitor or as a substrate is a previously unrecognized phenomenon among the serpins. Conversion of substrate PAI-1 to its inactive degradation product may constitute a pathway for the physiological regulation of PAI-1 activity.

摘要

相似文献

1
Identification of a conformationally distinct form of plasminogen activator inhibitor-1, acting as a noninhibitory substrate for tissue-type plasminogen activator.
J Biol Chem. 1992 Jun 15;267(17):11693-6.
2
Conversion of plasminogen activator inhibitor-1 from inhibitor to substrate by point mutations in the reactive-site loop.通过活性位点环中的点突变将纤溶酶原激活物抑制剂-1从抑制剂转化为底物。
J Biol Chem. 1994 Jul 29;269(30):19559-64.
3
Proteinase specificity and functional diversity in point mutants of plasminogen activator inhibitor 1.纤溶酶原激活物抑制剂1点突变体中的蛋白酶特异性和功能多样性
J Biol Chem. 1997 May 9;272(19):12662-6. doi: 10.1074/jbc.272.19.12662.
4
Conformational studies on plasminogen activator inhibitor (PAI-1) in active, latent, substrate, and cleaved forms.对活性、潜伏、底物和裂解形式的纤溶酶原激活物抑制剂(PAI-1)的构象研究。
Biochemistry. 1995 Jan 24;34(3):1064-9. doi: 10.1021/bi00003a042.
5
Resolution of Michaelis complex, acylation, and conformational change steps in the reactions of the serpin, plasminogen activator inhibitor-1, with tissue plasminogen activator and trypsin.丝氨酸蛋白酶抑制剂纤溶酶原激活物抑制剂-1与组织纤溶酶原激活物及胰蛋白酶反应中米氏复合物的解离、酰化及构象变化步骤
Biochemistry. 2001 Oct 2;40(39):11742-56. doi: 10.1021/bi0107290.
6
Identification of determinants involved in binding of tissue-type plasminogen activator-plasminogen activator inhibitor type 1 complexes to HepG2 cells.组织型纤溶酶原激活物 - 1型纤溶酶原激活物抑制剂复合物与HepG2细胞结合所涉及的决定因素的鉴定。
J Biol Chem. 1990 Aug 25;265(24):14093-9.
7
Vitronectin governs the interaction between plasminogen activator inhibitor 1 and tissue-type plasminogen activator.玻连蛋白调控纤溶酶原激活物抑制剂1与组织型纤溶酶原激活物之间的相互作用。
J Biol Chem. 1991 Jun 5;266(16):10700-7.
8
Structural basis of latency in plasminogen activator inhibitor-1.纤溶酶原激活物抑制剂-1中潜伏状态的结构基础。
Nature. 1992 Jan 16;355(6357):270-3. doi: 10.1038/355270a0.
9
Neutralization of plasminogen activator inhibitor-1 inhibitory properties: identification of two different mechanisms.纤溶酶原激活物抑制剂-1抑制特性的中和作用:两种不同机制的鉴定。
Biochim Biophys Acta. 1997 Feb 8;1337(2):257-66. doi: 10.1016/s0167-4838(96)00173-2.
10
Conformational changes of the reactive-centre loop and beta-strand 5A accompany temperature-dependent inhibitor-substrate transition of plasminogen-activator inhibitor 1.反应中心环和β链5A的构象变化伴随纤溶酶原激活物抑制剂1的温度依赖性抑制剂-底物转变。
Eur J Biochem. 1996 Oct 1;241(1):38-46. doi: 10.1111/j.1432-1033.1996.0038t.x.

引用本文的文献

1
Plasminogen Activator Inhibitors in Thrombosis: Structural Analysis and Potential Natural Inhibitors.血栓形成中的纤溶酶原激活物抑制剂:结构分析与潜在的天然抑制剂
ACS Omega. 2025 Jun 19;10(25):27348-27362. doi: 10.1021/acsomega.5c02926. eCollection 2025 Jul 1.
2
MicroRNA-34 and gastrointestinal cancers: a player with big functions.微小RNA-34与胃肠道癌症:一个功能强大的参与者。
Cancer Cell Int. 2024 May 9;24(1):163. doi: 10.1186/s12935-024-03338-w.
3
Plasminogen activator inhibitor 1 is not a major causative factor for exacerbation in a mouse model of SARS-CoV-2 infection.
纤溶酶原激活物抑制剂 1 不是 SARS-CoV-2 感染小鼠模型加重的主要致病因素。
Sci Rep. 2023 Feb 22;13(1):3103. doi: 10.1038/s41598-023-30305-8.
4
A Narrative Review on Plasminogen Activator Inhibitor-1 and Its (Patho)Physiological Role: To Target or Not to Target?纤溶酶原激活物抑制剂-1 的综述及其(病理)生理学作用:靶向还是不靶向?
Int J Mol Sci. 2021 Mar 8;22(5):2721. doi: 10.3390/ijms22052721.
5
Targeting PAI-1 in Cardiovascular Disease: Structural Insights Into PAI-1 Functionality and Inhibition.心血管疾病中靶向纤溶酶原激活物抑制剂-1:纤溶酶原激活物抑制剂-1功能及抑制作用的结构见解
Front Cardiovasc Med. 2020 Dec 22;7:622473. doi: 10.3389/fcvm.2020.622473. eCollection 2020.
6
TP53/miR-34a-associated signaling targets expression in human pancreatic cancer.TP53/miR-34a 相关信号通路靶基因在人胰腺癌中的表达。
Aging (Albany NY). 2020 Jan 27;12(3):2777-2797. doi: 10.18632/aging.102776.
7
Molecular mechanism of two nanobodies that inhibit PAI-1 activity reveals a modulation at distinct stages of the PAI-1/plasminogen activator interaction.两种抑制纤溶酶原激活物抑制剂-1(PAI-1)活性的纳米抗体的分子机制揭示了PAI-1/纤溶酶原激活剂相互作用不同阶段的调节作用。
J Thromb Haemost. 2020 Mar;18(3):681-692. doi: 10.1111/jth.14716. Epub 2020 Feb 20.
8
Discovery and characterisation of an antibody that selectively modulates the inhibitory activity of plasminogen activator inhibitor-1.发现并鉴定一种可选择性调节纤溶酶原激活物抑制剂-1 抑制活性的抗体。
Sci Rep. 2019 Feb 7;9(1):1605. doi: 10.1038/s41598-019-38842-x.
9
Plasminogen Activator Inhibitor 1 for Predicting Sepsis Severity and Mortality Outcomes: A Systematic Review and Meta-Analysis.纤溶酶原激活物抑制剂 1 预测脓毒症严重程度和死亡结局的价值:系统评价和荟萃分析。
Front Immunol. 2018 Jun 18;9:1218. doi: 10.3389/fimmu.2018.01218. eCollection 2018.
10
uPA/uPAR and SERPINE1 in head and neck cancer: role in tumor resistance, metastasis, prognosis and therapy.头颈部癌症中的尿激酶型纤溶酶原激活物/尿激酶型纤溶酶原激活物受体(uPA/uPAR)和丝氨酸蛋白酶抑制剂E1(SERPINE1):在肿瘤耐药、转移、预后及治疗中的作用
Oncotarget. 2016 Aug 30;7(35):57351-57366. doi: 10.18632/oncotarget.10344.